45 related articles for article (PubMed ID: 38708541)
1. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer.
Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussein M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE
Future Oncol; 2024; 20(16):1047-1055. PubMed ID: 38357801
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma.
Trouiller JB; Nikolaidis GF; Macabeo B; Meyer N; Gerlier L; Schlueter M; Laramee P
Eur J Health Econ; 2024 Jun; 25(4):641-653. PubMed ID: 37433888
[TBL] [Abstract][Full Text] [Related]
3. Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.
Schreck KC; Strowd RE; Nabors LB; Ellingson BM; Chang M; Tan SK; Abdullaev Z; Turakulov R; Aldape K; Danda N; Desideri S; Fisher J; Iacoboni M; Surakus T; Rudek MA; Bettegowda C; Grossman SA; Ye X
Clin Cancer Res; 2024 May; 30(10):2048-2056. PubMed ID: 38446982
[TBL] [Abstract][Full Text] [Related]
4. Disseminated intravascular coagulation induced by the combination therapy of encorafenib and binimetinib in a melanoma case.
Komatsu S; Horimoto K; Kato J; Sato S; Kobayashi E; Matsuda I; Takada K; Uhara H
J Dermatol; 2024 Jun; 51(6):e218-e219. PubMed ID: 38293725
[No Abstract] [Full Text] [Related]
5.
Imai T; Shoji H; Hirano H; Matsuguma K; Awatsu T; Hirose T; Okita N; Takashima A; Kato K
CNS Oncol; 2024 Jun; 13(1):2347824. PubMed ID: 38869444
[TBL] [Abstract][Full Text] [Related]
6. A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
Baik C; Cheng ML; Dietrich M; Gray JE; Karim NA
Adv Ther; 2024 May; ():. PubMed ID: 38698170
[TBL] [Abstract][Full Text] [Related]
7. Correction to: A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600EMutant Metastatic Non-Small Cell Lung Cancer.
Baik C; Cheng ML; Dietrich M; Gray JE; Karim NA
Adv Ther; 2024 Jun; ():. PubMed ID: 38833145
[No Abstract] [Full Text] [Related]
8. [Dramatic response to encorafenib plus binimetinib in a patient with leukemoid reaction from metastatic melanoma.].
Cerro M; Maccallini MT; Russillo M
Recenti Prog Med; 2024 May; 115(5):13e-16e. PubMed ID: 38708541
[TBL] [Abstract][Full Text] [Related]
9. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
10. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
11. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.
Trojaniello C; Festino L; Vanella V; Ascierto PA
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS).
Gogas H; Dummer R; Ascierto PA; Arance A; Mandalà M; Liszkay G; Garbe C; Schadendorf D; Krajsová I; Gutzmer R; Sileni VC; Dutriaux C; Yamazaki N; Loquai C; Queirolo P; Jan de Willem G; Sellier AT; Suissa J; Murris J; Gollerkeri A; Robert C; Flaherty KT
Eur J Cancer; 2021 Jul; 152():116-128. PubMed ID: 34091420
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients.
Indini A; Mandalà M
Expert Opin Drug Saf; 2020 Oct; 19(10):1229-1236. PubMed ID: 32857940
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]